Canagliflozin treatment of Hispanic and non-Hispanic patients with type 2 diabetes in a US managed care setting

References

• Centers for Disease Control and Prevention. National Diabetes Statistics Report, 2014. Atlanta, GA, United States: Centers for Disease Control and Prevention, 2015. Available at: http://www.cdc.gov/diabetes/data/statistics/2014statisticsreport.html [Last accessed 17 August 2015]
   Google Scholar
• Kanaya AM, Herrington D, Vittinghoff E, et al. Understanding the high prevalence of diabetes in U.S. south Asians compared with four racial/ethnic groups: the MASALA and MESA studies. Diab Care 2014;37:1621-8
   PubMed Web of Science ®Google Scholar
• Sigma Consortium, Estrada K, Aukrust I, et al. Association of a low-frequency variant in HNF1A with type 2 diabetes in a Latino population. JAMA 2014;311:2305-14
   PubMed Web of Science ®Google Scholar
• Piccolo RS, Pearce N, Araujo AB, McKinlay JB. The contribution of biogeographical ancestry and socioeconomic status to racial/ethnic disparities in type 2 diabetes mellitus: results from the Boston Area Community Health Survey. Ann Epidemiol 2014;24:648-54, 54 e1
   PubMed Web of Science ®Google Scholar
• Lynch CP, Gebregziabher M, Axon RN, et al. Geographic and racial/ethnic variations in patterns of multimorbidity burden in patients with type 2 diabetes. J Gen Intern Med 2014;30:25-32
   PubMed Web of Science ®Google Scholar
• Lopez L, Golden SH. A new era in understanding diabetes disparities among U.S. Latinos – all are not equal. Diab Care 2014;37:2081-3
   PubMed Web of Science ®Google Scholar
• Yracheta JM, Alfonso J, Lanaspa MA, et al. Hispanic Americans living in the United States and their risk for obesity, diabetes and kidney disease: genetic and environmental considerations. Postgrad Med 2015;127:503-10
   PubMed Web of Science ®Google Scholar
• Hazel-Fernandez L, Li Y, Nero D, et al. Racial/ethnic and gender differences in severity of diabetes-related complications, health care resource use, and costs in a Medicare population. Pop Health Manage 2015;18:115-22
   PubMed Web of Science ®Google Scholar
• Dominguez K, Penman-Aguilar A, Chang MH, et al. Vital signs: leading causes of death, prevalence of diseases and risk factors, and use of health services among Hispanics in the United States – 2009–2013. Morb Mortal Week Rep 2015;64:469-78
   PubMed Web of Science ®Google Scholar
• Livingston G, Minushkin, S, Cohn, D. Hispanics and Health Care in the United States: Access, Information, and Knowledge. Princeton, NJ: 2008. Available at: http://www.pewhispanic.org/2008/08/13/hispanics-and-health-care-in-the-united-states-access-information-and-knowledge/ [Last accessed 17 August 2015]
   Google Scholar
• Johnsen M. Latinos see diabetes as biggest health concern for their families. Drug Store News. 2014. Available at: http://www.drugstorenews.com/article/survey-latinos-see-diabetes-biggest-health-concern-their-families [Last accessed 17 August 2015]
   Google Scholar
• Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diab Care 2015;38:140-9
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Executive summary: standards of medical care in diabetes – 2014. Diabetes Care 2014;37(Suppl 1):S5-13
   PubMed Web of Science ®Google Scholar
• Kirk JK, Passmore LV, Bell RA, et al. Disparities in A1C levels between Hispanic and non-Hispanic white adults with diabetes: a meta-analysis. Diab Care 2008;31:240-6
   PubMed Web of Science ®Google Scholar
• Laiteerapong N, Fairchild PC, Chou CH, et al. Revisiting disparities in quality of care among US adults with diabetes in the era of individualized care, NHANES 2007–2010. Med Care 2015;53:25-31
   PubMed Web of Science ®Google Scholar
• Selvin E, Parrinello CM, Sacks DB, Coresh J. Trends in prevalence and control of diabetes in the United States, 1988–1994 and 1999–2010. Ann Intern Med 2014;160:517-25
   PubMed Web of Science ®Google Scholar
• Campos C. Addressing cultural barriers to the successful use of insulin in Hispanics with type 2 diabetes. Southern Med J 2007;100:812-20
   PubMed Web of Science ®Google Scholar
• Janssen Pharmaceuticals I. Invokana [Prescribing Information]. Janssen Pharmaceuticals Inc., 2015. Available at: http://www.invokanahcp.com/safety-information/safety-and-tolerability-profile [Last accessed 17 August 2015]
   Google Scholar
• Stenlof K, Cefalu WT, Kim KA, et al. Long-term efficacy and safety of canagliflozin monotherapy in patients with type 2 diabetes inadequately controlled with diet and exercise: findings from the 52-week CANTATA-M study. CMRO 2014;30:163-75
   Google Scholar
• Wilding JP, Blonde L, Leiter LA, et al. Efficacy and safety of canagliflozin by baseline HbA1c and known duration of type 2 diabetes mellitus. J Diab 2015;29:438-44
   Web of Science ®Google Scholar
• Schernthaner G, Gross JL, Rosenstock J, et al. Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial. Diab Care 2013;36:2508-15
   PubMed Web of Science ®Google Scholar
• Cefalu WT, Stenlof K, Leiter LA, et al. Effects of canagliflozin on body weight and relationship to HbA1c and blood pressure changes in patients with type 2 diabetes. Diabetologia 2015;58:1183-7
   PubMed Web of Science ®Google Scholar
• Davidson J, Aguilar R, Lavalle-Gonzalez F, et al. Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus by Hispanic/Latino ethnicity. Presented to the 23rd Annual Scientific and Clinical Congress of the American Association of Clinical Endocrinologists, 14–18 May 2014, Las Vegas, NV, USA
   Google Scholar
• Davidson J, Aguilar R, Lavalle-Gonzalez F, et al. Effects of canagliflozin, an SGLT2 inhibitor, in Hispanic/Latino patients with type 2 diabetes mellitus in the United States. Presented to the 18th National Hispanic Medical Association's Annual Conference, March 2014, Washington, DC, USA
   Google Scholar
• Davidson JA, Aguilar R, Lavalle González FJ, et al. Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus of different ethnicities. Ethnicity Dis 2015;26: In Press
   Google Scholar
• National Center for Health Statistics. International Classification of Diseases and Injuries, Clinical Modification version 9. Centers for Disease Control and Prevention, 2002. Available at: ftp://ftp.cdc.gov/pub/Health_Statistics/NCHS/Publications/ICD-9/ucod.txt [Last accessed 17 August 2015]
   Google Scholar
• United States Census Bureau. Census Regions and Divisions of the United States. In: US Department of Commerce, Economics, and Statistics Administration. U.S. Census Bureau. Available at: http://www2.census.gov/geo/pdfs/maps-data/maps/reference/us_regdiv.pdf [Last accessed 17 August 2015]
   Google Scholar
• Levy DE, Byfield SD, Comstock CB, et al. Underutilization of BRCA1/2 testing to guide breast cancer treatment: black and Hispanic women particularly at risk. Gen Med 2011;13:349-55
   Google Scholar
• Jain A, Marshall J, Buikema A, et al. Autism occurrence by MMR vaccine status among US children with older siblings with and without autism. JAMA 2015;313:1534-40
   PubMed Web of Science ®Google Scholar
• Young BA, Lin E, Von Korff M, et al. Diabetes complications severity index and risk of mortality, hospitalization, and healthcare utilization. Am J Man Care 2008;14:15-23
   PubMed Web of Science ®Google Scholar
• Chang HY, Weiner JP, Richards TM, et al. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Man Care 2012;18:721-6
   PubMed Web of Science ®Google Scholar
• Buysman EKCW, Henk HJ, Rupnow MFT. Characteristics and short-term outcomes of patients with type 2 diabetes mellitus treated with canagliflozin in a real-world setting. CMRO 2014;2014:1-7
   Google Scholar
• Meckley LM, Miyasato G, Kokkotos F, et al. An observational study of glycemic control in canagliflozin treated patients. Curr Med Res Opin 2015;31:1479–86
   Google Scholar
• Kirkman MS, Rowan-Martin MT, Levin R, et al. Determinants of adherence to diabetes medications: findings from a large pharmacy claims database. Diab Care 2015;38:604-9
   PubMed Web of Science ®Google Scholar
• Colon E, Giachello A, McIver L, et al. Diabetes and depression in the Hispanic/Latino Community. Clin Diab 2013;31:43-5
   Google Scholar
• United States Census Bureau. Current Population Survey, 2014. Income and insurance status questions asked respondents about previous year (2013). 2014. Available at: http://www.census.gov/cps/data/cpstablecreator.html [Last accessed 17 August 2015]
   Google Scholar
• United States Congress. Patient Protection and Affordable Care Act, 42 USC 18001.(2010). Available at: https://www.congress.gov/bill/111th-congress/house-bill/3590 [Last accessed 17 August 2015]
   Google Scholar
• DeFrank J, Bowling JM, Rimer BK, et al. Triangulating differential nonresponse by race in a telephone survey. Prev Chronic Dis 2007;4:1-10
   Google Scholar
• Caballero AE. Understanding the Hispanic/Latino patient. Am J Med 2011;124(10 Suppl):S10-15
   PubMed Web of Science ®Google Scholar